Relevant Health alumni, Agewell Biometrics is in the running to win the Medstartr Open Crowd Challenge. You can suppoprt them and help end the epidemic of avoidable falls in the elderly. Make a tax deductable donation or show your support by 'Liking' the campaign and help Agewell over the finish line.
Agewell's Equilibrium™ platform is the first automated, fall prevention system. Using a smartphone, and soon a wearable sensor, Equilibrium™ measures strength, balance and physical function in order to identify fall risk, giving an early window of opportunity to take the right preventative steps before a fall happens.
One in three people aged 65 years and older fall every year - the leading cause of injury-related deaths amongst older adults, in addition to causing loss of independence, social isolation and depression. As many as 50% of these falls could be prevented with simple exercises, but only once a problem is identified. Equilibrium™ gives you the early warning for fall risk and soon you'll be able to download it on your iOS or Android phone as a simple-to-use app.
A diagnostic test developer, miDIAGNOSTICS, has inked a deal with a Baltimore-based healthcare startup emocha to provide a way to conduct diagnostic tests through silicon chips and transmit those lab test results through the cloud, according to a press release.
Montgomery County’s Business Innovation Network is pleased to announce that Rockville’s own ReveraGen BioPharma, Inc., a Rockville Innovation Center tenant, granted an option to in-license vamorolone to Swiss company Actelion Ltd. This agreement marks the first tech transfer out of Children’s National Medical Center. Prior to moving to the Rockville Innovation Center, ReveraGen made their home at the Shady Grove Innovation Center.
Actelion Ltd and ReveraGen BioPharma, Inc., announced via press release that they entered into an agreement on November 3, 2016. By this agreement, Actelion has obtained an exclusive option to in-license ReveraGen’s lead compound vamorolone for the treatment of Duchenne Muscular Dystrophy at two different stages in its development.
The cofounders of startup that is looking to develop a vaccine for HPV are heading to a Buffalo accelerator.
PathoVax is among the new class of startups at 43North. A panel of judges and experts selected them as finalists after a big, fancy pitch competition held in late October meant to showcase Buffalo’s emerging tech chops.
Qiagen N.V., a leading global provider of sample to insight solutions, announced the validation of new and improved sequencing chemistry for its GeneReader NGS System, the world’s first complete Sample to Insight solution making the benefits of next-generation sequencing (NGS) accessible to any laboratory.
Qiagen published new, excellent performance data of the Qiagen GeneReader NGS System using the new sequencing chemistry and Qiagen’s GeneRead QIAact Actionable Insights Tumor Panel. Data generated from the GeneReader NGS System with the new chemistry showed 100% concordance with results of Qiagen’s FDA approved therascreen KRAS RGQ PCR assay, the company’s CE-labelled therascreen RAS Extension Pyro Assay as well as with an alternative next-generation sequencing (NGS) sequencer from another vendor. In this study, 42 metastatic colorectal cancer FFPE samples were tested with previously confirmed RAS mutational status.
Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, today announced they are now accepting applications for their Cancer Discovery Incubator Award.
After experiencing partnering success and a $315 million deal with Japan-based Astellas Pharma Inc. for their LAMP-Vax platform technology in allergy, Immunomic Therapeutics, in concert with BioHealth Innovation, is giving back to the region's growing scientific community with the Cancer Discovery Incubator Award. The incubator will enable and accelerate beginning ventures aimed at offering measurable change in oncological healt
Tuesday, November 29th | 10:00am – 12:00 pm Rockville Innovation Center, 155 Gibbs Street, Rockville, MD 20850
Hosted by BioHealth Innovation
You’ve probably heard about the Cloud, Big Data and Machine Learning, but where does the hype end and the true value of these technologies begin? Can, or should, your business leverage these technologies? Mark Weston and Matt Puglisi from Netrias LLC (www.netrias.com) will describe the current state of the art for Cloud computing, Big Data and Machine Learning to help you better leverage these technologies for your business.
Mark Weston, Chief Software Architect, is a software engineer with extensive experience in applying distributed database technologies to problems at scale. Matt Puglisi, Chief Executive Officer is a seasoned leader with successful experience as a technology company executive, a leader of research and development efforts, government service, and military service
Please RSVP by November 22nd to Joyce Debrowski (jdebrowski@scheerpartners.com | (301) 279-2222). The event is open to the first 30 registrants only.
Building Specifications:
- Up to 31,764 SF Available
- Rare large block of existing Class-A laboratory/office
- Heavily improved with casework, sinks, fume hoods, autoclaves, cold rooms
- Certified BSL-3 Suite
- Building is fully backed-up by emergency generator
- Complimentary membership to Alexandria FitLab fitness center
- Close proximity to Metro, FDA, NIH, lodging, restaurants and retail amenities
The mosquito-borne Zika virus — described in recent, grim federal warnings as "not controllable by current technologies"— could become an important source of hope for a regrouped Novavax Inc.
Gaithersburg-based Novavax (NASDAQ: NVAX), still recovering from stunning negative results from its phase 3 trials of its lead respiratory syncytial virus (RSV) vaccine for older adults, said this week that it had "exciting preclinical data" from its new Zika program.
A new five-year collaboration between Johns Hopkins University and biopharmaceutical company Bristol-Myers Squibb aims to determine why some patients being treated for cancer respond to immunotherapy drugs called checkpoint blockers and some do not, and to develop more effective combination immunotherapies.
Projects included in the collaboration will span laboratory research on patients' tumor samples and several early-stage clinical trials led by Johns Hopkins scientists at the Bloomberg-Kimmel Institute for Cancer Immunotherapy.
Thu, November 17, 20164:30 PM – 8:30 PM EST
Join more than 400 of the region’s business and government leaders for the Economic Alliance of Greater Baltimore’s Annual Meeting, November 17, 2016 at the Baltimore Marriott Waterfront. While Maryland is known for its history and culture, food and beautiful landscape, this year’s annual meeting will celebrate one of the region’s greatest assets – the people – as they tell their stories. The program will recognize the region’s growing companies and those who make our community a world-class market in which to live, work, learn and invest.
NOVEMBER 16, 2016 5:00pm to 6:30pm
Host: UM BioPark & Wexford Science + Technology
Location: UM BioPark Invent & Advance Conference Rooms 801 W. Baltimore Street Baltimore Maryland 21201
Please join the BioPark's Monthly Networking Event. Mingle with UM Venture program managers, BioPark tenants, and UMB faculty and staff.
Nominations are open for the 2017 Industry Awards Celebration. This will be our 29th year of recognizing the companies and individuals in the region who make a difference.
The Tech Council ignites the power of three by bringing together a trio of industries that are accelerating our local ecosystem—technology, life sciences, and health IT. It’s our mission to make this region a top three innovation economy, so we’re redefining what’s possible and helping to shape the future through ideation, collaboration, and innovation.
Join BioBuzz as we partner with BioIT Solutions to celebrate their 10th Anniversary at Growlers in Gaithersburg on November 16, 2016. BioIT Solutions offers a range of services from enterprise systems built on their 1Platform4 Suite for advanced computational, workflow, and data management systems to IT strategy, architecture and management consulting. The 1Platform Suite consists of a software foundation on which various highly configurable modules are assembled and tailored to each client’s specifications and needs.
The company was founded by IT experts who have worked in the biotechnology sector for over 20 years in a variety of information-technology capacities, including senior positions as CIO, and directors of Bioinformatics, Quality Systems and Clinical Systems at companies including Human Genome Sciences (now part of GlaxoSmithKline). The breadth of our experience makes us an ideal partner for early-stage companies, as well as those with legacy systems in need of modernization.
Thursday, December 1, 2016 | 6:00 – 8:30 p.m.
The more than 25 Showcase companies are some of the best from the robust U.S.-Israel Business ecosystem in fields including cyber security, homeland security, bio/pharma, environmental, healthcare, medical device and software. For more information on the companies, go to MarylandIsrael.org/showcase2016.
miDIAGNOSTICS, global developer of integrated diagnostic solutions for the point-of-need, announces that it has established a collaboration with emocha Mobile Health Inc. from Baltimore, MD, USA. A Johns Hopkins startup company, emocha has developed a platform of digital mobile applications that streamline the continuum of care. The goal of the collaboration is to enable mobile health solutions based on the miniaturized products for point-of-need under development by miDIAGNOSTICS.
Concerns over the role of the Center for Medicare & Medicaid Innovation could lead to legislation intended to hinder the agency and slow its attempts to further the goal of paying providers for value rather than volume.
While no specific legislative language has surfaced, multiple sources confirmed that Republicans upset with what they say is overreach by the CMS Innovation Center, also known as CMMI, are considering a legislative response. A few Republicans have previously said they would support repealing the agency entirely or zeroing out its budget. More modest efforts could include banning mandatory participation in payment models.
Get in the habit of producing good financial reports every single month. But you need more than just standard financial reports. You need a Management Dashboard that monitors critical metrics that may not pop out of your accounting reports. These monthly reports are a learning opportunity: What did we think would happen? What actually happened? Why was there a difference? Are we on track to hit our key milestones?
The day following the election of Donald J. Trump as President, a survey of leaders in biotechnology in the United States, conducted by GENETIC ENGINEERING & BIOTECHNOLOGY NEWS (GEN), showed that Trump’s presidency will negatively impact NIH research funding as well as STEM education; a plurality said it will also spark a “brain drain” as foreign-born researchers educated in American universities will be more likely to leave.
An end to Obamacare and a less aggressive approach to drug pricing expected
Pharmaceutical stocks surged in Europe on Wednesday as Republican Donald Trump’s U.S. presidential election win led investors to conclude the threat of tough action on drug pricing had receded.
Five Top Intellectual Property Legal Experts and a Room Filled with Life Science and Healthcare Entrepreneurs…what could possibly happen?
Strategies for Start-ups (and Non-Start-ups) to Maintain, Protect and Unlock their Intellectual Property.
The workshop is intended for non-lawyers to understand IP issues and answer questions on just about every aspect of IP including; Copyrights, Trade Secrets, Trademarks, Patents, licensing, IP Due Diligence, IP Strategy, etc.
BioFactura is seeking highly motivated applicants with an entrepreneurial spirit for an open position in our biosimilar development programs. We are looking for qualified candidates with an associates, bachelor or masters degree in the life sciences with highly relevant skills and bench experience. The selected candidate will participate in the development and validation of various biosimilar product assays. In this position, the candidate will be responsible for planning, conducting, execution and analysis of experiments using various techniques in protein analysis. Relevant skills include HPLC/U-HPLC (HILIC, RP, SEC, CEX, AEX, affinity), capillary electrophoresis (CE), mass spec, SDS-PAGE, IEF, ELISA, qPCR. Knowledge of protein purification methods and process development/scale-up is a plus. Knowledge of Good Laboratory Practices (GLP) including analytical method qualification/validation and current Good Manufacturing Practices (cGMP) are desired. Experience in the preparation and delivery of oral and written presentations as well as participation in the preparation and submission of grants and/or manuscripts for publication are a plus. Excellent communication skills and the ability to analyze and interpret data, design appropriately controlled experiments independently, and maintain up-to-date laboratory notebooks are a must. This is an excellent opportunity to gain valuable experience with an innovative, small, young Biotech company and build a career in the biopharmaceutical industry. Candidates should feel comfortable working in a high risk/potential high reward environment and able to work overtime and weekends as project needs are determined.
